TAT and neoplasm: To determine the role of PI3K in Tat-mediated promotion of vIL-6-induced tumors, we treated the tumor-bearing mice with LY294002, a specific PI3K inhibitor for 5 times at the indicated times starting on day 10 post-inoculation.